Business Wire

Valbiotis Obtains Patent for Its Active Substance TOTUM•63 in China, a Large Potential Market for the Prevention of Type 2 Diabetes and Metabolic Diseases

Share

Regulatory News:

Valbiotis (FR0013254851 - ALVAL, eligible for the PEA / SME), a Research and Development company committed to scientific innovation for preventing and combating metabolic diseases, announces that it has obtained a patent in China for TOTUM•63, issued by the China National Intellectual Property Administration (CNIPA). This patent protects the composition and use of TOTUM•63 for the prevention of type 2 diabetes and metabolic diseases until 2035. China, whose economic development has been accompanied by an explosion of metabolic disorders since the 2000s, is now believed to have the largest prediabetic population in the world, with an estimated 390 million people (35% of the adult population)1.

Sébastien PELTIER, CEO of Valbiotis, comments: "We are honored to obtain this Chinese patent. It is the recognition of our ability to develop plant-based active substances by another major global market, after Europe and the United States. In this new and rapidly developing territory, metabolic diseases and type 2 diabetes are critical public health issues. With this patent, we can now envision making our active substance TOTUM•63 available to a very large population, whose need for the prevention of metabolic diseases is huge. This is an exciting prospect and a challenge that we will undertake with great determination, alongside our partner Nestlé Health Science."

The rise of a significant market for the prevention of metabolic diseases in China

Since the 2000s and the acceleration of its economic development, China has been facing a dramatic increase in excess weight, obesity and the associated metabolic diseases such as type 2 diabetes. The rapid change in eating habits and living conditions in the world's largest population has led to an alarming situation for the Chinese authorities: at the end of 2020, 34% of adults in China were overweight and 16% obese, i.e. one adult in two at metabolic risk, an increase of 20% in 20 years2.
As a result of this weight gain in all age groups, blood glucose disorders are becoming more prevalent in the country: the most recent estimates indicate a 35% prevalence of prediabetes among adults, while type 2 diabetes is almost at 11%1. These rates are now equivalent to those recorded in the United States, but in a population four times larger. 390 million adults in China are supposed to be prediabetic1, compared to 86 million in the United States3.

To meet the new health needs of the population, the Chinese healthcare market has grown rapidly, driven by structural reforms and the development of the middle class4. In 2018, China ranked 2nd in the global pharmaceutical market (8.2% of global sales), behind the United States5.

TOTUM•63 now benefits from global patent protection, including in China and 4 other new countries

The patent obtained in China gives exclusive rights to use TOTUM•63 within Chinese territory until 2035. Like the patents already obtained, this patent grants extensive rights that protect, in particular: the active substance TOTUM•63's plant extract and biomolecule composition, the possible combination with other products or substances and, above all, the specific use of this innovation in the field of metabolic diseases.

In addition to China, similar patents for TOTUM•63 have recently been obtained in Japan, Mexico, Indonesia and New Zealand, bringing the total number of countries in which TOTUM•63 is now protected to 48.

TOTUM•63 patent is the subject of a global patent filing strategy in more than 60 countries, including Europe and North America. It is co-owned along with the CNRS (Centre National de la Recherche Scientifique), Clermont Auvergne University and La Rochelle University, each long-standing academic partners of Valbiotis since the Company's creation in 2014.

About TOTUM•63
TOTUM•63 is a unique and patented combination of 5 plant extracts, with high potential to target the physiopathological mechanisms of Type 2 Diabetes.
TOTUM•63 has already been proven safe and effective in healthy human volunteers during a Phase I/II clinical study. The results of the international randomized, placebo-controlled Phase II study showed that TOTUM•63 reduced fasting and 2-hour blood sugar levels, two risk factors for Type 2 Diabetes, in prediabetics compared to placebo. In these subjects, who also had abdominal obesity, TOTUM•63 significantly reduced body weight and waist circumference.
TOTUM•63 benefits from intellectual property granted in the main markets worldwide: Europe (covering 39 countries), the United States, Russia, China, Japan, Mexico, Indonesia, Israel, South Africa, New-Zealand and national phases are underway in more than 10 countries including Brazil and Australia. The ability to produce TOTUM•63 industrially, in compliance to North American and European standards, has been validated. TOTUM•63 already has marketing authorizations related to its status in Europe.
In 2020, Valbiotis has signed a global and long-term partnership with Nestlé Health Science for the development and worldwide commercialization of TOTUM•63. This unique partnership in the field of Nutrition Health plans that TOTUM•63 will be put on the market by Nestlé Health Science at a global level, possibly before obtaining a health claim, depending on the areas. It will also provide funding for the latest development stages of TOTUM•63.

About Valbiotis
Valbiotis is a Research & Development company committed to scientific innovation for preventing and combating metabolic diseases in response to unmet medical needs.
Valbiotis has adopted an innovative approach, aiming to revolutionize healthcare by developing a new class of health nutrition products designed to reduce the risk of major metabolic diseases, based on a multi-target approach enabled by the use of plant-based ingredients.
Its products are intended to be licensed to players in the health sector.
Created at the beginning of 2014 in La Rochelle, the Company has forged numerous partnerships with leading academic centers. The Company has established three sites in France: Périgny, La Rochelle (17) and Riom (63).
Valbiotis is a member of the "BPI Excellence" network and has been recognized as an "Innovative Company" by the BPI label. Valbiotis has also been awarded "Young Innovative Company" status and has received major financial support from the European Union for its research programs via the European Regional Development Fund (ERDF). Valbiotis is a PEA-SME eligible company.
For more information about Valbiotis, please visit: www.valbiotis.com

Name: Valbiotis
ISIN code: FR0013254851
Mnemonic code: ALVAL
EnterNext© PEA-PME 150

This press release contains forward-looking statements about Valbiotis' objectives. Valbiotis considers that these projections are based on rational hypotheses and the information available to the company at the present time. However, in no way does this constitute a guarantee of future performance, and these projections may be reconsidered based on changes in economic conditions and financial markets, as well as a certain number of risks and uncertainties, including those described in the Valbiotis registration document, approved by the French Financial Markets Regulator (AMF) on 31 July 2020 (application number R 20-018). This document is available on the Company's website (www.valbiotis.com).
This press release, as well as the information contained herein, does not constitute an offer to sell or subscribe to, or a solicitation to purchase or subscribe to, Valbiotis' shares or securities in any country.

1 Limin Wang et al. JAMA. 2017;317(24):2515-2523.
2 Chinese national nutrition and chronic disease report 2020, National Health Commission, www.sciencesetavenir.fr/sante/plus-d-un-chinois-sur-deux-desormais-en-surpoids_150360 (as viewed on April 27, 2021).
3 AEC Partners data on Valbiotis' key markets, 2019.
4daxueconseil.fr/marche-des-medicaments-en-vente-libre-en-chine/ (as viewed on April 27, 2021).
5 Bilan Economique, Les Entreprises du Médicament, 2019, p. 40 ; www.leem.org/sites/default/files/2019-09/250719-BilanEco2019_6.pdf (as viewed on April 27, 2021).

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Corporate communication / Valbiotis
Carole ROCHER / Marc DELAUNAY
+33 5 46 28 62 58
media@valbiotis.com

Financial communication / Actifin
Stéphane RUIZ
+33 1 56 88 11 14
sruiz@actifin.fr

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

SES Expands Cloud Leadership as Amazon Web Services Direct Connect Partner17.6.2021 08:50:00 CEST | Press release

SES today announced it has joined the Amazon Web Services (AWS) Direct Connect Delivery Partner program. Through a technical and business review process, AWS validated SES’s ability to connect its customers directly to their AWS services over its network of multi-orbit satellites. This provides SES customers flexible, secure, reliable access to their cloud-based applications and services from virtually any location around the world. This is a major advantage to both enterprises and government users who require reliable bandwidth while working in remote locations. SES is the first satellite operator to achieve AWS Direct Connect Partner status. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210616006077/en/ SES Expands Cloud Leadership as Amazon Web Services Direct Connect Partner (Photo: Business Wire) As an AWS Direct Connect Delivery Partner, SES can provide enterprises and governments with dedicated connectivity between v

SIG SolarCAD II: Solar Thermal Delivering 80°C Daily Even in Winter Months17.6.2021 07:47:00 CEST | Press release

The new SIG SolarCAD II solar thermal power plant, designed and installed by the Geneva-based TVP Solar and inaugurated in February this year, has proven its high performance in winter conditions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210616005846/en/ Even covered in snow, TVP Solar thermal panels supply SIG target temperatures and thermal energy (Photo: TVP Solar) More than 157 MWh (1.92 kWh/m²/day) of solar hot water at over 80°C were delivered to the district heat network (CAD) between January and April, i.e. 30% of the annual energy performance target of 516 MWh set between the Services Industriels de Genève (SIG) and TVP Solar. Michel Monnard, thermal director at SIG and project instigator, is delighted: “the solar plant’s performance significantly exceeded our expectations, being remarkably efficient during the cold and poor sunshine winter period when the CAD has the most need for heat.” The TVP solar thermal

C3 AI and NCS Form Strategic Partnership to Deliver Enterprise AI Applications Across Asia-Pacific17.6.2021 06:00:00 CEST | Press release

C3 AI (NYSE:AI), the Enterprise AI application software company, and NCS, a leading technology services provider and member of the Singtel Group, today announced a strategic partnership focused on delivering enterprise AI solutions to clients in Southeast Asia (SEA) and Australia/New Zealand (ANZ) across multiple industries, including telecommunications, government, financial services, transportation, and more. This agreement represents C3 AI’s first strategic partnership with a telecommunications group. NCS will leverage its deep domain experience and technology expertise in serving governments and businesses in SEA and ANZ, investing up to S$10 million to develop and deploy enterprise AI applications created on the C3 AI® Suite. C3 AI’s solutions will also be deployed across Singtel, Optus, and other affiliated telecommunications networks to bring the advantages of enterprise AI to their operations and clients. As the leader in enterprise AI applications, C3 AI’s offerings include th

MicroPort CRM Announces European Launch of Alizea TM and Borea TM Pacemakers With Bluetooth® Connectivity and Streamlined Remote Monitoring17.6.2021 06:00:00 CEST | Press release

MicroPort CRM, a pioneering company in the field of Cardiac Rhythm management, headquartered in France with global operations,announced today the European launch of AlizeaTM and BoreaTM pacemakers after receiving the CE mark under the new Medical Device Regulation (MDR - 2017/745). The devices are equipped with Bluetooth®1 technology for streamlined remote monitoring when paired with the SmartView ConnectTM home monitor. AlizeaTM and BoreaTM connected pacemakers allow cardiologists to monitor the devices remotely, saving patients the need to travel to hospital for a simple routine examination and thus reducing burden on the healthcare system. Today, with more than 500 000 patients per year implanted with a pacemaker across Europe, connected cardiac technologies are needed more than ever. "MicroPort CRM has always been committed to providing medical devices with the most advanced technology and features to improve patient outcomes and reduce the burden on the healthcare system”, said Be

Dialpad Introduces a Smarter, More Reliable Calling Experience for Microsoft Teams Users17.6.2021 01:57:00 CEST | Press release

Dialpad Inc., the industry leader in AI-powered communication and collaboration, today announced its platform integration with Microsoft Teams, a leading solution for team collaboration and engagement. Dialpad for Microsoft Teams is a cloud-native direct routing integration that seamlessly connects Dialpad’s enterprise-grade telephony features and award-winning Voice Intelligence (Vi™) capabilities into the Microsoft Teams native environment. According to Microsoft’s Hybrid Work Trend Index, workers report that their productivity has either remained the same or increased over the past year. As work methods continue to evolve, Dialpad is at the forefront, creating better, smarter and more seamless communication experiences. With Dialpad direct routing at the heart of the integration, Microsoft Teams users have access to Dialpad’s global calling capabilities with PSTN connectivity in 49 countries in addition to sophisticated inbound and outbound calling features. Powered by automatic spe

LiveArt Market Opens Trading16.6.2021 21:00:00 CEST | Press release

LiveArt is pleased to announce the public launch of LiveArt Market, the digital peer-to-peer marketplace that places control into the hands of sellers and buyers. LiveArt Market began limited, invitation-only trading last week and has already achieved sales approaching $5 million, with more than 1,000 works of art valued at approximately $120 million in the pipeline for sale. Prices have ranged between $50,000 and $500,000, with works by Amoako Boafo and Ed Clark commanding six-figure sums. Early offerings available for purchase include works by Derrick Adams, Jean-Michel Basquiat, Yayoi Kusama, Pablo Picasso and Andy Warhol, among others. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210616005925/en/ Yayoi Kusama, Little Flower, 1952, Gouache, pastel, ink, pen on paper, 11.5 x 8.5 in (Photo: Business Wire) LiveArt puts collectors in control by providing participants with one destination for real-time information and an eff

Smiths Medical Issues Worldwide Notification Regarding the Recall of Jelco ® Hypodermic Needle-Pro ® Fixed Needle Insulin Syringe With Skewed Graduation Markings16.6.2021 20:00:00 CEST | Press release

Smiths Medical has become aware of specific models and lots of Jelco® Hypodermic Needle-Pro® Fixed Needle Insulin Syringes that may exhibit skewed odd number line graduation markings on their syringe barrels. Markings skewed approximately 20 degrees upward have been identified. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210616005888/en/ Jelco® Hypodermic Needle-Pro® Fixed Needle Insulin Syringes skewed graduation marking on the syringe barrel. (Photo: Business Wire) Affected Models and Lot Numbers: Model Number Name Lot Number 4428-1 Jelco® Hypodermic Needle-Pro® Fixed Needle Insulin Syringe 28Gx1/2” 1CC 4046543 and 4062235 4429-1 Jelco® Hypodermic Needle-Pro® Fixed Needle Insulin Syringe 29Gx1/2” 1CC 4014096, 4031846, 4031845, 4040734, 4043536, 4046545, 4046546, 4062239, 4062240, 4062238 and 4062242 Please reference the attachment for an illustration of the skewed graduation marking on the syringe barrel. As a result of